Physician profile
William T Ashburn
NPI 1356327456
$2,536.21
in general payments reported to CMS, 2019-2025
27 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $303 · 2021: $689 · 2022: $403 · 2023: $434 · 2024: $300 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $344.70 | 2022-2025 | |
| Abbvie INC. | $340.71 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $240.54 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $147.43 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $143.89 | 2021 | |
| Neurocrine Biosciences, INC. | $133.95 | 2019-2021 | |
| Amgen INC. | $115.38 | 2019-2022 | |
| Lilly USA, LLC | $114.27 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Allergan, INC. | $69.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $61.19 | 2019-2021 | |
| Astellas Pharma US INC | $51.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.49 | 2019-2021 | |
| Dexcom, INC. | $34.90 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $32.22 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2024 | Xifaxan |
| Upsher-Smith Laboratories LLC | $25.45 | 2021 | |
| Pfizer INC. | $23.17 | 2019-2020 | |
| Abbott Laboratories | $17.93 | 2024 | Freestyle Libre 3 |
| Vbi Vaccine (Delaware) INC. | $17.83 | 2022 | |
| Hologic Sales and Service, LLC | $16.24 | 2023 | Aptima |
| Teva Pharmaceuticals USA, INC. | $15.56 | 2021 | |
| Daiichi Sankyo INC. | $15.18 | 2020 | |
| Sobi, INC | $14.17 | 2019 | |
| Merck Sharp & Dohme LLC | $13.10 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Novartis Pharmaceuticals Corporation | $12.84 | 2021 | |
| Amarin Pharma, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ashburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.